Abstract：
Androgenetic alopecia (AGA) is the most common form of alopecia, affecting up to 80% of men and 50% of women in the course of their life. AGA is caused by a progressive reduction in the diameter, length and pigmentation of the hair, resulting from the effects of the testosterone metabolite dihydrotestosterone (DHT) on androgen-sensitive hair follicles. Clinical presentation is different in men and women. Trichoscopy is used routinely in patients with androgenetic alopecia, for diagnosis and differential diagnosis with other diseases, allowing staging of severity and monitoring the progress of the disease and the response to treatment. Medical treatment of AGA includes topical minoxidil, antiandrogen agents, 5-alpha reductase inhibitors and many other options. This guideline for the treatment of androgenetic alopecia has been developed by an Italian group of experts taking into account the Italian pharmacological governance. The article is adapted from the original of the European Dermatology Forum (EDF) in collaboration with the European Academy of Dermatology and Venereology (EADV). It summarizes evidence-based and expert-based recommendations (S3 level).
摘要：
雄激素性脱发（AGA）是最常见的脱发形式，影响到80%的男性和50%的女性。AGA是由直径逐渐减小引起的，头发的长度和色素沉着，由于睾酮代谢物二氢睾酮（DHT）对雄激素敏感的毛囊的影响。男性和女性的临床表现不同。脊髓镜检查通常用于雄激素性脱发患者，用于与其他疾病的诊断和鉴别诊断，允许对严重程度进行分期，并监测疾病的进展和对治疗的反应。AGA的医学治疗包括局部米诺地尔，抗雄激素药，5-α还原酶抑制剂和许多其他选择。这个治疗雄激素性脱发的指南是由一个意大利专家组考虑到意大利的药理管理而制定的。本文改编自欧洲皮肤病学论坛（EDF）与欧洲皮肤病与性病学会（EADV）合作的原著。它总结了基于证据和基于专家的建议（S3级别）。
